Sep 2026· Small Methods· pp.
e71046
· 0 citations· 103 references
Medicine
TL;DR
A "trinity" synergistic design paradigm is proposed, which exploits pathological mitochondrial signals as dual-functional cues for both subcellular navigation and catalytic activation, thereby achieving temporal coupling of "targeting enrichment" and "responsive activation."
Abstract
Mitochondrial dysfunction represents a common pathological hub in tumors, neurodegenerative diseases, cardiovascular diseases, and inflammatory degenerative diseases. Nanozymes offer new opportunities for precision intervention. However, inadequate targeting and uncontrollable activity remain major obstacles to their clinical translation. This review proposes a "trinity" synergistic design paradigm, which exploits pathological mitochondrial signals as dual-functional cues for both subcellular navigation and catalytic activation, thereby achieving temporal coupling of "targeting enrichment" and "responsive activation." Within this framework, we first summarize the three major categories of nanozyme material systems and their mitochondrial targeting strategies. Subsequently, we systematically analyze the structural design and activation mechanisms of endogenous, exogenous, and multi-stimulus synergistic responsive nanozymes. We also establish a cross-scale effect chain model that cascades from catalytic events to mitochondrial metabolic remodeling, programmed cell death, and immune regulation. On this basis, we comprehensively review the therapeutic applications of these nanozymes in oncology, neurological disorders, cardiovascular diseases, and inflammatory degenerative diseases. Finally, we analyze the critical challenges confronting this field and provide perspectives on future directions, with the aim of offering theoretical references and research ideas for the development of mitochondria-targeted intelligent nanomedicines.
Mitophagy is a selective autophagic process responsible for the elimination of damaged or dysfunctional mitochondria, playing a critical role in maintaining mitochondrial quality control and cellular homeostasis. Dysregulated mitophagy has been implicated in the pathogenesis of numerous diseases, including neurodegener...
Jiaenli Bolati, Junjie Yang, Yue-Qi Yan et al.· Biomedical Materials· 0 citations
Tumor multidrug resistance remains a major driver of treatment failure, largely due to the adaptive plasticity that enables cancer cells to evade conventional therapies. Ferroptosis, a non-apoptotic cell-death modality driven by iron-dependent lipid peroxidation, offers a mechanistically distinct route to overcome ther...
Kun-Teng Yang, Xiang-Ling Ren, Qiong Wu et al.· Biochimica et biophysica act...· 0 citations
This review provides a structured synthesis that spans from the biological basis of mitochondrial function and transfer to the broad applications of nanomaterials in mitochondria‐targeted therapies, with a dedicated analysis of their roles in mitochondrial targeting, functional modulation, and gene editing.
Yuan-Yuan Su, Zhi-Yan Gong, Jiao Mu et al.· Advancement of science· 0 citations
Piezoelectric nanozymes offer a versatile platform for multimodal cancer therapy and represent a promising paradigm for developing strategies for precise, non-invasive cancer therapy through localized ROS generation and modulation of the TME.
Akanksha Deshwal, A. Vimal, Prachi Nirwan et al.· Cancer nanotechnology· 0 citations
Abstract With the rapidly aging global population, neurodegenerative diseases (NDDs) present an escalating challenge to public health. The complex, self-perpetuating pathological network of NDDs, encompassing aberrant protein aggregation, chronic neuroinflammation, synaptic impairment, and mitochondrial dysfunction, si...
Hang-Lu Li, Shuang-Yan Jiang, Xin-Yi Liu et al.· International Journal of Nan...· 0 citations
Ferroptosis, a unique form of regulated, iron-dependent cell death, has emerged as a therapeutic mechanism for a range of diseases, including cancer, neurodegeneration, metabolic disorders, and organ injuries. However, the clinical translation of small-molecule ferroptosis modulators remains limited due to poor speci...
Zhong-Qiang Zhu, Ling Jiang, Tong Sun et al.· ACS Nano· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.